Institutional Fund
Arch Venture Management, LLC
Chicago, ILCIK 12744035 filings on record
Portfolio Value
$677.09M
Q1 2026
Holdings
10
Reported positions
New Buys
1
Opened this quarter
QoQ Change
+3.9%
from $651.68M
Portfolio Value Trend
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeTop Allocations
Largest positions by weight
- Maze Therapeutics Inc18.2%
- Rapport Therapeutics Inc17.2%
- Vir Biotechnology Inc17.1%
- Erasca Inc16.9%
- Beam Therapeutics Inc16.0%
- Lyell Immunopharma Inc9.6%
- Other5.0%
Portfolio Holdings
10 positions · Q1 2026
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Maze Therapeutics Inc | 4.12M | $122.98M | 18.2% | 0 | Held |
| 2 | Rapport Therapeutics Inc | 3.73M | $116.67M | 17.2% | 0 | Held |
| 3 | Vir Biotechnology Inc | 12.92M | $115.73M | 17.1% | 0 | Held |
| 4 | Erasca Inc | 7.09M | $114.74M | 16.9% | −3.96M | Reduced |
| 5 | Beam Therapeutics Inc | 4.54M | $108.19M | 16.0% | 0 | Held |
| 6 | Lyell Immunopharma Inc | 3.25M | $65.14M | 9.6% | +488.1K | Added |
| 7 | Generate Biomedicines Inc | 1.94M | $24.31M | 3.6% | +1.94M | New |
| 8 | 10x Genomics Inc | 217.8K | $4.62M | 0.7% | −519.7K | Reduced |
| 9 | Gossamer Bio Inc | 8.06M | $2.65M | 0.4% | 0 | Held |
| 10 | Q32 Bio Inc | 320.5K | $2.06M | 0.3% | 0 | Held |